Invention Publication
- Patent Title: SLC13A5 GENE THERAPY VECTORS AND USES THEREOF
-
Application No.: US18683101Application Date: 2022-09-29
-
Publication No.: US20240342314A1Publication Date: 2024-10-17
- Inventor: Rachel M BAILEY
- Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
- Applicant Address: US TX Austin
- Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
- Current Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
- Current Assignee Address: US TX Austin
- International Application: PCT/US2022/077274 2022.09.29
- Date entered country: 2024-02-12
- Main IPC: A61K48/00
- IPC: A61K48/00 ; A61P25/28 ; C07K14/705 ; C12N15/86
Abstract:
The present disclosure provides methods and compositions for the treatment of diseases and genetic disorders linked to SLC13A5 loss, misfunction and/or deficiency, including neurological disorders, diseases, and conditions such as epileptic encephalopathy. The methods and compositions of the present disclosure comprise rAAV vectors and rAAV viral vectors comprising transgene nucleic acid molecules comprising nucleic acid sequences encoding for an SLC13A5 polypeptide.
Information query
